Japanese encephalitis virus-based replicon RNAs/particles as an expression system for HIV-1 Pr55Gag that is capable of producing virus-like particles

Virus Research

Volumn 144, Issue 1-2, 2009, Pages 298-305

  Yun, Sang Im ^a   Song, Byung Hak ^a   Koo, Yongbum ^b   Jeon, Iksoo ^c   Byun, Sung June ^c   Park, Jong Hyeon ^d   Joo, Yi Seok ^d   Kim, Seok Yong ^a   Lee, Young Min ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Inje University   (South Korea)

^c National Institute of Animal Science   (South Korea)

^d Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

Author keywords

Foreign gene delivery; Human immunodeficiency virus; Japanese encephalitis virus; Replicon; Virus like particle

Indexed keywords

PR55 GAG PROTEIN; REV PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

3' UNTRANSLATED REGION; ARTICLE; CELL STRAIN 3T3; CELL STRAIN BHK; CONTROLLED STUDY; CYTOPLASM; ENCEPHALOMYOCARDITIS VIRUS; GENE DELETION; GENE EXPRESSION SYSTEM; GENE INSERTION; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERNAL RIBOSOME ENTRY SITE; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REPLICON; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ANIMALS; CELL LINE; CRICETINAE; ENCEPHALITIS VIRUS, JAPANESE; GENETIC VECTORS; HUMANS; MICE; PROTEIN PRECURSORS; REPLICON; RNA, VIRAL; TRANSFECTION; VIROSOMES;

ALPHAVIRUS; CRICETINAE; ENCEPHALOMYOCARDITIS VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; JAPANESE ENCEPHALITIS VIRUS;

EID: 69249232052     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2009.04.014     Document Type: Article

References (72)

1. Adamson C.S., and Freed E.O. Human immunodeficiency virus type 1 assembly, release, and maturation. Adv. Pharmacol. 55 (2007) 347-387
2. Afonina E., Neumann M., and Pavlakis G.N. Preferential binding of poly(A)-binding protein 1 to an inhibitory RNA element in the human immunodeficiency virus type 1 gag mRNA. J. Biol. Chem. 272 (1997) 2307-2311
3. Agapov E.V., Frolov I., Lindenbach B.D., Prágai B.M., Schlesinger S., and Rice C.M. Noncytopathic Sindbis virus RNA vectors for heterologous gene expression. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 12989-12994
4. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
5. André S., Seed B., Eberle J., Schraut W., Bültmann A., and Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 72 (1998) 1497-1503
6. Brinton M.A. The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu. Rev. Microbiol. 56 (2002) 371-402
7. Caley I.J., Betts M.R., Irlbeck D.M., Davis N.L., Swanstrom R., Frelinger J.A., and Johnston R.E. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71 (1997) 3031-3038
8. Calisher C.H., and Gould E.A. Taxonomy of the virus family Flaviviridae. Adv. Virus Res. 59 (2003) 1-19
9. Casimiro D.R., Tang A., Perry H.C., Long R.S., Chen M., Heidecker G.J., Davies M.E., Freed D.C., Persaud N.V., Dubey S., Smith J.G., Havlir D., Richman D., Chastain M.A., Simon A.J., Fu T.M., Emini E.A., and Shiver J.W. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J. Virol. 76 (2002) 185-194
10. Chambers T.J., Hahn C.S., Galler R., and Rice C.M. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44 (1990) 649-688
11. Crotty S., Miller C.J., Lohman B.L., Neagu M.R., Compton L., Lu D., Lü F.X., Fritts L., Lifson J.D., and Andino R. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J. Virol. 75 (2001) 7435-7452
12. Cullen B.R. Retroviruses as model systems for the study of nuclear RNA export pathways. Virology 249 (1998) 203-210
13. Deml L., Bojak A., Steck S., Graf M., Wild J., Schirmbeck R., Wolf H., and Wagner R. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J. Virol. 75 (2001) 10991-11001
14. Fayzulin R., Scholle F., Petrakova O., Frolov I., and Mason P.W. Evaluation of replicative capacity and genetic stability of West Nile virus replicons using highly efficient packaging cell lines. Virology 351 (2006) 196-209
15. Felber B.K., Zolotukhin A.S., and Pavlakis G.N. Posttranscriptional control of HIV-1 and other retroviruses and its practical applications. Adv. Pharmacol. 55 (2007) 161-197
16. Freed E.O., and Martin M.A. HIVs and their replication. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5th ed. (2007), Lippincott Williams & Wilkins, Philadelphia, PA 2107-2185
17. Ganser-Pornillos B.K., Yeager M., and Sundquist W.I. The structural biology of HIV assembly. Curr. Opin. Struct. Biol. 18 (2008) 203-217
18. Gao F., Li Y., Decker J.M., Peyerl F.W., Bibollet-Ruche F., Rodenburg C.M., Chen Y., Shaw D.R., Allen S., Musonda R., Shaw G.M., Zajac A.J., Letvin N., and Hahn B.H. Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. AIDS Res. Hum. Retrov. 19 (2003) 817-823
19. Gehrke R., Heinz F.X., Davis N.L., and Mandl C.W. Heterologous gene expression by infectious and replicon vectors derived from tick-borne encephalitis virus and direct comparison of this flavivirus system with an alphavirus replicon. J. Gen. Virol. 86 (2005) 1045-1053
20. Gheysen D., Jacobs E., de Foresta F., Thiriart C., Francotte M., Thines D., and De Wilde M. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59 (1989) 103-112
21. Goff S.P. Retroviridae: the retroviruses and their replication. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5th ed. (2007), Lippincott Williams & Wilkins, Philadelphia, PA 1999-2069
22. Göttlinger H.G. The HIV-1 assembly machine. AIDS 15 Suppl 5 (2001) S13-20
23. Graf M., Bojak A., Deml L., Bieler K., Wolf H., and Wagner R. Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J. Virol. 74 (2000) 10822-10826
24. Haffar O., Garrigues J., Travis B., Moran P., Zarling J., and Hu S.L. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J. Virol. 64 (1990) 2653-2659
25. Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., Sharpe S.A., Cook N., Smith G.L., Watkins D.I., Cranage M.P., and McMichael A.J. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73 (1999) 7524-7532
26. Harvey T.J., Anraku I., Linedale R., Harrich D., Mackenzie J., Suhrbier A., and Khromykh A.A. Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. J. Virol. 77 (2003) 7796-7803
27. Heinz F.X., Collett M.S., Purcell R.H., Gould E.A., Howard C.R., Houghton M., Moorman R.J.M., Rice C.M., and Thiel H.-J. Family Flaviviridae. In: van Regenmortel M.H.V., Fauquet C.M., and Bishop D.H.L. (Eds). Virus Taxonomy: Classification and Nomenclature of Viruses (2000), Academic Press, San Diego, CA 859-878
28. Huang Y., Kong W.P., and Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 75 (2001) 4947-4951
29. Johnson P.R., Schnepp B.C., Connell M.J., Rohne D., Robinson S., Krivulka G.R., Lord C.I., Zinn R., Montefiori D.C., Letvin N.L., and Clark K.R. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J. Virol. 79 (2005) 955-965
30. Jones C.T., Patkar C.G., and Kuhn R.J. Construction and applications of yellow fever virus replicons. Virology 331 (2005) 247-259
31. Karacostas V., Nagashima K., Gonda M.A., and Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 8964-8967
32. Khromykh A.A., and Westaway E.G. Subgenomic replicons of the flavivirus Kunjin: construction and applications. J. Virol. 71 (1997) 1497-1505
33. Kong W., Tian C., Liu B., and Yu X.F. Stable expression of primary human immunodeficiency virus type 1 structural gene products by use of a noncytopathic sindbis virus vector. J. Virol. 76 (2002) 11434-11439
34. Kuritzkes D.R., and Walker B.D. HIV-1, pathogenesis, clinical manifestations, and treatment. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5th ed. (2007), Lippincott Williams & Wilkins, Philadelphia, PA 2187-2214
35. + T cells. Virology 243 (1998) 78-93
36. + T-cell responses in mice. J. Virol. 81 (2007) 11840-11849
37. Lindenbach B.D., Thiel H.-J., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5th ed. (2007), Lippincott Williams & Wilkins, Philadelphia, PA 1101-1152
38. Lingappa J.R., Hill R.L., Wong M.L., and Hegde R.S. A multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free system. J. Cell Biol. 136 (1997) 567-581
39. Lo M.K., Tilgner M., Bernard K.A., and Shi P.Y. Functional analysis of mosquito-borne flavivirus conserved sequence elements within 3′ untranslated region of West Nile virus by use of a reporting replicon that differentiates between viral translation and RNA replication. J. Virol. 77 (2003) 10004-10014
40. Maldarelli F., Martin M.A., and Strebel K. Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation. J. Virol. 65 (1991) 5732-5743
41. Mason P.W., Shustov A.V., and Frolov I. Production and characterization of vaccines based on flaviviruses defective in replication. Virology 351 (2006) 432-443
42. Matano T., Kobayashi M., Igarashi H., Takeda A., Nakamura H., Kano M., Sugimoto C., Mori K., Iida A., Hirata T., Hasegawa M., Yuasa T., Miyazawa M., Takahashi Y., Yasunami M., Kimura A., O'Connor D.H., Watkins D.I., and Nagai Y. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 199 (2004) 1709-1718
43. McGettigan J.P., Pomerantz R.J., Siler C.A., McKenna P.M., Foley H.D., Dietzschold B., and Schnell M.J. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J. Virol. 77 (2003) 237-244
44. Megati S., Garcia-Hand D., Cappello S., Roopchand V., Masood A., Xu R., Luckay A., Chong S.Y., Rosati M., Sackitey S., Weiner D.B., Felber B.K., Pavlakis G.N., Israel Z.R., Smith L.R., Eldridge J.H., Sidhu M.K., and Egan M.A. Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses. Vaccine 26 (2008) 5083-5094
45. Mergener K., Fäcke M., Welker R., Brinkmann V., Gelderblom H.R., and Kräusslich H.G. Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology 186 (1992) 25-39
46. Molenkamp R., Kooi E.A., Lucassen M.A., Greve S., Thijssen J.C., Spaan W.J., and Bredenbeek P.J. Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins. J. Virol. 77 (2003) 1644-1648
47. Ngumbela K.C., Ryan K.P., Sivamurthy R., Brockman M.A., Gandhi R.T., Bhardwaj N., and Kavanagh D.G. Quantitative effect of suboptimal codon usage on translational efficiency of mRNA encoding HIV-1 gag in intact T cells. PLoS ONE 3 (2008) e2356
48. Pang X., Zhang M., and Dayton A.I. Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV. BMC Microbiol. 1 (2001) 28-36
49. Pavlakis G.N. The molecular biology of human immunodeficiency virus Type 1. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). AIDS: Biology, Diagnosis, Treatment and Prevention vol. 4 (1997), Lippincott-Raven Publishers, PA 45-74
50. Pierson T.C., Diamond M.S., Ahmed A.A., Valentine L.E., Davis C.W., Samuel M.A., Hanna S.L., Puffer B.A., and Doms R.W. An infectious West Nile virus that expresses a GFP reporter gene. Virology 334 (2005) 28-40
51. Pollard V.W., and Malim M.H. The HIV-1 Rev protein. Annu. Rev. Microbiol. 52 (1998) 491-532
52. Qiu J.T., Song R., Dettenhofer M., Tian C., August T., Felber B.K., Pavlakis G.N., and Yu X.F. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J. Virol. 73 (1999) 9145-9152
53. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., Montefiori D., Roberts A., Buonocore L., and Rose J.K. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 (2001) 539-549
54. Rosen C.A., Terwilliger E., Dayton A., Sodroski J.G., and Haseltine W.A. Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 2071-2075
55. Royer M., Hong S.S., Gay B., Cerutti M., and Boulanger P. Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J. Virol. 66 (1992) 3230-3235
56. Sakalian M., and Hunter E. Molecular events in the assembly of retrovirus particles. Adv. Exp. Med. Biol. 440 (1998) 329-339
57. Schneider R., Campbell M., Nasioulas G., Felber B.K., and Pavlakis G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J. Virol. 71 (1997) 4892-4903
58. Schwartz S., Campbell M., Nasioulas G., Harrison J., Felber B.K., and Pavlakis G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J. Virol. 66 (1992) 7176-7182
59. Schwartz S., Felber B.K., and Pavlakis G.N. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J. Virol. 66 (1992) 150-159
60. Shi P.Y., Tilgner M., and Lo M.K. Construction and characterization of subgenomic replicons of New York strain of West Nile virus. Virology 296 (2002) 219-233
61. Shioda T., and Shibuta H. Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 175 (1990) 139-148
62. Smith A.J., Cho M.I., Hammarskjöld M.L., and Rekosh D. Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles. J. Virol. 64 (1990) 2743-2750
63. Swanstrom R., and Wills J.W. Synthesis, assembly, processing of viral proteins. In: Coffin J.M., Hughes S.H., and Varmus H.E. (Eds). Retroviruses (1997), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 263-334
64. Vajdy M., Gardner J., Neidleman J., Cuadra L., Greer C., Perri S., O'Hagan D., and Polo J.M. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J. Infect. Dis. 184 (2001) 1613-1616
65. Varnavski A.N., and Khromykh A.A. Noncytopathic flavivirus replicon RNA-based system for expression and delivery of heterologous genes. Virology 255 (1999) 366-375
66. Vogt V.M. Proteolytic processing and particle maturation. Curr. Top. Microbiol. Immunol. 214 (1996) 95-131
67. Wang C.T., Lai H.Y., and Li J.J. Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release. J. Virol. 72 (1998) 7950-7959
68. Xin K.Q., Urabe M., Yang J., Nomiyama K., Mizukami H., Hamajima K., Nomiyama H., Saito T., Imai M., Monahan J., Okuda K., Ozawa K., and Okuda K. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum. Gene Ther. 12 (2001) 1047-1061
69. Yun S.I., Choi Y.J., Yu X.F., Song J.Y., Shin Y.H., Ju Y.R., Kim S.Y., and Lee Y.M. Engineering the Japanese encephalitis virus RNA genome for the expression of foreign genes of various sizes: implications for packaging capacity and RNA replication efficiency. J. Neurovirol. 13 (2007) 522-535
70. Yun S.I., Kim S.Y., Rice C.M., and Lee Y.M. Development and application of a reverse genetics system for Japanese encephalitis virus. J. Virol. 77 (2003) 6450-6465
71. Yun S.I., and Lee Y.M. Japanese encephalitis virus: molecular biology and vaccine development. In: Kalitzky M., and Borowski P. (Eds). Molecular Biology of the Flavivirus (2006), Horizon Scientific Press, Norwich, UK 225-271
72. zur Megede J., Chen M.C., Doe B., Schaefer M., Greer C.E., Selby M., Otten G.R., and Barnett S.W. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 74 (2000) 2628-2635